Opus Genetics, INC

Opus Genetics announced revised clinical data from its Phase 1/2 trial of OPGx-BEST1 for BEST1-related retinal diseases, showing encouraging safety and efficacy signals.

Opus Genetics announced positive low-dose Cohort 1 data from its Phase 1/2 trial of OPGx-BEST1 for BEST1-related retinal diseases, showing clinically meaningful improvements in visual function and structural changes, alongside a favorable safety profile.

Opus Genetics announced Q2 2026 financial results, highlighting progress in gene therapy programs for inherited retinal diseases, with key data expected soon and cash runway extending into 2029.

Opus Genetics highlighted its expanding gene therapy pipeline for inherited retinal diseases (IRDs), with five programs targeting significant unmet needs and multiple clinical data readouts expected.

Opus Genetics provided an update on its gene therapy pipeline, highlighting progress in five Inherited Retinal Disease (IRD) programs and outlining upcoming clinical milestones.

Opus Genetics announced Q1 2026 financial results, highlighting progress in gene therapy programs for inherited retinal diseases and an extended cash runway into 2029.

Opus Genetics reports substantial cash reserves and progress in gene therapy trials, alongside significant financing activities and continued operational losses.

Opus Genetics reports a significant increase in R&D expenses for its inherited retinal disease pipeline, alongside a substantial swing in warrant liability fair value, impacting net loss for the first quarter of 2026.

Opus Genetics reported a significantly wider net loss in Q3 2025, driven by warrant liability changes and increased R&D for gene therapies, while securing new capital to advance its pipeline.

Opus Genetics reports increased cash reserves and significant progress in its gene therapy pipeline, despite rising operating expenses and continued net losses.

Opus Genetics reports its financial results for the first quarter of 2025, highlighting revenue from the Viatris license agreement and progress in its gene therapy programs.

Opus Genetics, formerly Ocuphire Pharma, has completed a merger, shifting its focus to gene therapies for inherited retinal diseases while advancing its existing ophthalmic programs.

Opus Genetics, a clinical-stage biopharmaceutical company, reported positive clinical trial results for its lead gene therapies, OPGx-LCA5 and OPGx-BEST1, alongside reduced net losses and increased cash reserves for fiscal year 2025.

Opus Genetics provides an update on its financial standing, gene therapy pipeline advancements, and strategic partnerships in its annual 10-K filing.

Ocuphire Pharma's 2023 annual report details the company's progress in developing novel therapies for retinal and refractive eye disorders, including the FDA approval of RYZUMVI and advancements in clinical trials for APX3330 and PS.

George Magrath, Chief Executive Officer and a Director of Opus Genetics, Inc., reported multiple transactions in common stock on September 9, 2026.

Cam Gallagher, a Director of Opus Genetics, Inc., reported multiple transactions in common stock on September 8, 2026.

Robert E. Gagnon, Chief Financial Officer of Opus Genetics, Inc., sold 28,000 shares of common stock on September 3, 2026 for $4.54 per share.

Benjamin R Yerxa, President and a Director of Opus Genetics, Inc., sold 7,429 shares of common stock on July 23, 2026 for $2.97 per share.

Joseph K Schachle, Chief Operating Officer of Opus Genetics, Inc., sold 4,644 shares of common stock on July 23, 2026 for $2.94 per share.

George Magrath, Chief Executive Officer and a Director of Opus Genetics, Inc., sold 9,475 shares of common stock on July 23, 2026 for $2.95 per share.

Opus Genetics, Inc. is calling its 2026 Annual Meeting of Stockholders to vote on key proposals including the election of directors, executive compensation, and a significant increase in authorized common stock to support future growth and financing needs.

Opus Genetics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Opus Genetics will hold its annual meeting of stockholders virtually on April 30, 2025, to vote on director elections, auditor ratification, executive compensation, preferred stock conversion, and meeting adjournment.

Opus Genetics updates its proxy statement after the Sooch Group withdraws its director nominees for the upcoming annual meeting.

Opus Genetics files its definitive proxy statement and urges stockholders to vote for its board nominees, highlighting the company's transformation and progress while criticizing a campaign by former CEO Mina Sooch to replace a majority of directors.

Opus Genetics is urging shareholders to vote for its director nominees amidst a proxy fight initiated by a stockholder group led by former CEO Mina Sooch.

Foundation Fighting Blindness RD Fund and Foundation Fighting Blindness, Inc. have reduced their stake in Opus Genetics, Inc. below the 5% reporting threshold.

Foundation Fighting Blindness entities have reduced their beneficial ownership in Opus Genetics, Inc. to 8.0% following a share sale on December 9, 2025.

Foundation Fighting Blindness Retinal Degeneration Fund and Foundation Fight Blindness, Inc. have increased their beneficial ownership in Opus Genetics, Inc. to 15.9% of common stock following the automatic conversion of preferred shares.

Balyasny Asset Management L.P. and affiliated entities have reported a beneficial ownership stake of 6.64% in Opus Genetics Inc., indicating a shift in institutional holding.

Perceptive Advisors and Joseph Edelman have filed a Schedule 13G reporting a 9.99% beneficial ownership stake in Opus Genetics, Inc.

Caligan Partners LP and David Johnson have reported beneficial ownership of 8.5% of Opus Genetics, Inc. common stock as of March 31, 2026.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 7.18% of Opus Genetics Inc. common stock as of March 31, 2026.

Several Bios-affiliated entities and individuals have reported a combined beneficial ownership of 4.53% in Opus Genetics, Inc. common stock.

Adage Capital Management, L.P., along with individuals Robert Atchinson and Phillip Gross, has filed a Schedule 13G, reporting beneficial ownership of 8.47% of Opus Genetics, Inc. common stock as of March 31, 2026.